Johnson & Johnson subsidiary Biosense Webster has received the approval to launch its Thermocool Smarttouch SF Catheter in the US to treat drug resistant paroxysmal atrial fibrillation (Afib).
It is based on direct contact force technology and provides uniform cooling while easing the fluid management process.
The Thermocool Smarttouch Catheter allows physicians the ability to create a stable application of contact force by providing direct, quantitative feedback in real time, which is displayed on the Carto 3 System monitor upon tissue contact
The catheter tip is fitted with a sensor which allows direct measurement of contact force applied on heart tissue.
The contact force reading is then transmitted through a coil to the Carto 3 System which creates real-time 3D maps of the heart during the minimally invasive catheter ablation procedures.
The device features a spring which moves to respond to contact force providing calculation in grams.
St David's Medical Centre Texas Cardiac Arrhythmia Institute executive medical director Dr Andrea Natale said: "The Thermocool Smarttouch SF Catheter represents a significant advancement for the clinical community.
"Conducted trials, including the Smart -AF and Smart-SF studies, have shown Biosense Webster technology enables physicians to achieve targeted stability in the defined contact force range, leading to shorter procedure times and enhanced results without compromising safety."
The recent Smart-AF trial of the catheter has suggested its safety while treating drug refractory paroxysmal atrial fibrillation also resulting to reduction in procedure time.